TELA Bio (TELA) Common Equity (2018 - 2026)

TELA Bio's Common Equity history runs 9 years deep, the most recent figure standing at -$5.2 million for Q1 2026.

• On a quarterly basis, Common Equity fell 128.7% year-over-year to -$5.2 million in Q1 2026; TTM through Mar 2026 was -$5.2 million, a 128.7% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 77.82% from the prior year.
• Common Equity retreated to -$5.2 million in Q1 2026 per TELA's latest filing, from $6.3 million in the prior quarter.
• Across five years, Common Equity topped out at $40.0 million in Q2 2023 and bottomed at -$6.3 million in Q3 2024.
• The 5-year median for Common Equity is $10.0 million (2022), against an average of $12.2 million.
• Across the five-year window, Common Equity jumped 2694.36% in 2023 and sank 128.7% in 2026, its largest moves.
• Year by year, Common Equity stood at $14.3 million in 2022, then soared by 31.99% to $18.9 million in 2023, then jumped by 50.72% to $28.5 million in 2024, then tumbled by 77.82% to $6.3 million in 2025, then slumped by 182.39% to -$5.2 million in 2026.
• Per Business Quant, the three latest TELA Common Equity figures stand at -$5.2 million (Q1 2026), $6.3 million (Q4 2025), and $1.6 million (Q3 2025).